Benchmark Has Buy Rating On Bio-Reference Labs (BRLI)

Benchmark Capital has a Buy rating and a $25 price target on shares of Bio-Reference Labs, Inc. BRLI.

In a note to clients, Benchmark writes, "Revenue in F1Q11 expanded 23% to $121.7 million, which exceeded the $119.1 million consensus and approached our $122.1 million forecast. Pro-forma EPS expanded 20% to match the $0.17 consensus and Benchmark estimates. There is no change to our earnings forecast or price target. We are encouraged that BRLI was able to meet the earnings consensus despite challenging weather in the quarter that ended in February. We believe this reflects strength in the core business and supports the possibility for positive future earnings surprises."

Shares of BRLI gained $1.30 yesterday to close at $22.30, a gain of 6.2%.